Highly significant scaffolds to design and synthesis of cholinesterase inhibitors as anti-Alzheimer agents

(E-pub Abstract Ahead of Print)

Author(s): Yaghoub Pourshojaei*, Khalil Eskandari*, Ali Asadipour.

Journal Name: Mini-Reviews in Medicinal Chemistry

Become EABM
Become Reviewer


Alzheimer, a progressive disease, is a common term for memory loss which its progression leads to interfere with daily life via serious enough influence on cognitive abilities. Considering to the cholinergic hypothesis, and based on X-ray crystallographic determination of the structure of acetylcholinesterase (AChE) enzyme, the level of acetylcholine (ACh, an important neurotransmitter associated with memory) in the hippocampus and cortex area of the brain has directly affect on Alzheimer. This fact encourages scientists to design and synthesis of a wide range of acetylcholinesterase inhibitors (AChEIs) to control the level of ACh brain with bearing in mind crystallographic structure of AChE enzyme and drugs approved by the Food and Drug Administration (FDA).

The AChEIs have slightly diverse pharmacological properties, but all of them work by inhibiting the segregation of ACh by blocking the AChE. Herein, we reviewed up to date reported significant scaffolds introduced as AChEIs.

Keywords: Cholinesterase inhibitors, Design, Synthesis, Dementia, Alzheimer disease.Cholinesterase inhibitors, Alzheimer disease

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/1389557519666190719143112
Price: $95